A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

NCT04981665 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Zhejiang University

Collaborators